FREE Daily Email Newsletter
Dendreon Gets Boost From Aetna Coverage Memo
October 1, 2012 4:02 am | News | CommentsWASHINGTON (AP) — Shares of biotech developer Dendreon Corp. rose Friday after health insurer Aetna said it would expand coverage of Provenge, the company's pricey prostate cancer drug.
Dendreon Falls on Data for Rival Cancer Drug
June 5, 2012 4:14 am | News | CommentsNEW YORK (AP) — Shares of Dendreon Corp. slumped Monday after Johnson & Johnson reported positive clinical data for a prostate cancer drug that competes with Dendreon's therapy Provenge.
Dendreon Falls as Analyst Starts Coverage
May 24, 2012 4:07 am | News | CommentsNEW YORK (AP) — Shares of Dendreon Corp. sank Wednesday after a Jefferies & Co. analyst said the company's prostate cancer therapy Provenge will be eclipsed by two newer competitors.
Dendreon Shares Fall After Disclosure of SEC Probe
May 17, 2012 9:14 am | News | CommentsWASHINGTON (AP) — Shares of biotech drugmaker Dendreon fell today on worries about an investigation into company conduct by financial regulators.
Dendreon Shares Fall After First Quarter Earnings Report
May 8, 2012 4:29 am | by The Associated Press | News | CommentsDendreon tumbled more than 12 percent in premarket trading Tuesday after the drug developer reported a loss and what an analyst described as "modest growth" for the company's only marketed product, the prostate cancer treatment Provenge.
Dendreon Sells Royalty Interest in Victrelis for $125M
December 7, 2011 5:17 am | by Lianne Dane | News | CommentsDendreon said Tuesday that it sold its royalty interest in Merck & Co.’s hepatitis C drug Victrelis (boceprevir) for $125 million in a move that is expected to strengthen the company’s cash holdings.
Dendreon Will Eliminate 500 Jobs to Slash Spending
September 9, 2011 5:03 am | News | CommentsSEATTLE (AP) — Dendreon Corp. said Thursday that it will eliminate 500 jobs, or more than a quarter of its work force, as it reduces costs to compensate for disappointing sales of its prostate cancer therapy Provenge.

